Top Industry Leaders in the Uterine Fibroid Market
Latest Uterine Fibroid Companies Update
December 2023:Gynesonics, a women's healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids, raised $42.5 million in funding to expand the commercialization of its Sonata procedure.
June 2023:Viveve Medical, a company developing non-invasive radiofrequency energy treatments for feminine health issues, acquired Emsella for $100 million, strengthening its market position in women's intimate health solutions.
July 2023:US Food and Drug Administration (FDA) approved Acessa Health's Acessa® System for the treatment of heavy menstrual bleeding associated with uterine fibroids. This approval provides a novel minimally invasive option for women suffering from this condition.
April 2023:Myovant launched a Phase 3 clinical trial evaluating the efficacy and safety of relugolix (YELNO) for the treatment of pain and heavy menstrual bleeding associated with uterine fibroids. This study could lead to a new oral medication option for managing fibroid symptoms.
List of Uterine Fibroid Key Companies in the Market
- GlaxoSmithKline plc
- Hoffmann-La Roche Ltd
- Pfizer Inc
- Novartis AG
- Bristol-Myers Squibb Company
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Amgen Inc, Medtronic
- Endo International plc
- Mylan N.V
- Sun Pharmaceutical Industries Ltd
- Hologic, Inc
- Smith & Nephew
- Merck & Co. Inc